{'fraction_non_alphanumeric': 0.02185792349726776, 'fraction_numerical': 0.020036429872495445, 'mean_word_length': 5.875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preclinical and clinical evaluation of 5‐fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma

Background. Approximately 140,000 new cases of colorectal carcinoma will be diagnosed in 1995 in the United States, and more than one‐third of these patients will die from progressive disease. Despite the modest improvement in response rate with chemotherapy, little improvement in patient survival has been noted. Consequently, the evaluation of new agents, modalities, and combinations is needed.